Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | GCKR | Q14397 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833507 | 0.81 | POLB (0.43) | POLBMLYCDPPARDAPLNRHSP90AA1 | |
| SCHEMBL6074694 | 0.81 | POLB (0.43) | POLBCNR1CNR2MLYCDGCK | |
| SCHEMBL12619939 | 0.80 | POLB (0.45) | POLBCNR1CNR2PPARDLOXL2 | |
| SCHEMBL12568268 | 0.77 | ALDH1A1 (0.56) | POLBGCKGCKRKMT2A | |
| SCHEMBL3126218 | 0.71 | POLB (0.52) | POLBCNR1CNR2PPARDKMT2A | |
| SCHEMBL16263907 | 0.69 | CFTR (0.61) | POLBCNR1CNR2PPARDKMT2A | |
| SCHEMBL28654691 | 0.69 | POLB (0.49) | POLBCNR1CNR2PPARDKMT2A | |
| SCHEMBL3134847 | 0.68 | POLB (0.56) | POLBPPARDKMT2A | |
| SCHEMBL1300785 | 0.68 | POLB (0.48) | POLBCNR1CNR2PPARDKMT2A | |
| SCHEMBL2702353 | 0.68 | CA1 (0.55) | POLBCNR1CNR2PPARDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | POLB 2266/4885CNR1 411/4885CNR2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.